Muscular

FDA
Stories Uncategorized

FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths

The U.S. Food and Drug Administration (FDA) has placed an immediate clinical hold on Sarepta Therapeutics’ investigational gene therapy trials for limb girdle muscular dystrophy following three patient deaths potentially linked to the company’s treatments. The agency announced the action on Friday, citing serious safety concerns and “unreasonable and significant risk” to study participants. The […]

Read More